⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 14, 1992New England Journal of MedicineOpen Access

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

View Full Paper

Ask AI

Bookmark

Share

Abstract

GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM:

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gutniak et al. (1992) studied this question.

synapsesocial.com/papers/6967d8a4e7c383ab6b6d7fc0 https://doi.org/10.1056/nejm199205143262003

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutOriginal Research · 1987 · 622 citations
2Comparison of the Effects of Various C-Terminal and NTerminal Fragment Peptides of Glucagon-Like Peptide-1 on Insulin and Glucagon Release from the Isolated Perfused Rat Pancreas*Original Research · 1989 · 110 citations
3Effects of Somatostatin on Gastrointestinal Propagation and Absorption of Oral Glucose in ManOriginal Research · 2009 · 98 citations
4Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose IntoleranceOriginal Research · 1979 · 4,958 citations